HEAT-NET Frontiers in Neurodegeneration: from bench to bedside

Preliminary program – HEAT-net Meeting –  September 6-8 (Mon-Wed), 2021

Start
13:00 Arrival
14:00 Welcome: Tiago Outeiro, Christine von Arnim, Martin Ingelsson, Alberto Lleó
14:05 Dean of University Medical Center Göttingen: Prof. Wolfgang Brück (invited)
Session 1
Synaptic dysfunction: where it all starts
14:15 – 14:30 Tiago Outeiro: Alpha-Synuclein at the synapse: dangerous interactions
14:30-14:45 Tara Spires: Synapse degeneration and resilience in ageing and neurodegeneration – the
role of microglia in synaptic degeneration in Alzheimer’s disease
14:45-15:00 Christine Stadelmann-Nessler: Neurodegenerative aspects of multiple sclerosis

Coffee Break: 15:00-15:30

Session 2
Preclinical models of neurodegeneration
15:30-15:45 Annakaisa Haapasalo: Effects of the C9orf72 repeat expansion in preclinical models of
frontotemporal lobar degeneration
15:45-16:00 Monica Garcia-Alloza: Alzheimer´s disease and diabetes mellitus: models and
translational implications
16:00-16:15 Melanie Meyer-Luehmann: Abeta seeding as a tool to study cerebral amyloidosis and
associated pathology

Coffee Break: 16:15-16:45

Session 3
Keynote lecture – moderator: Tiago Outeiro
16:45-17:15 Brian Bacskai: Imaging the pathophysiology of animal models of Alzheimer’s disease
17:15-17:30 Discussion
17:30 Welcome reception
19:00 Speakers’ dinner

Coffee Break: 16:15-16:45

Coffee: 8:30

Session 4
Brief talks by junior investigators
9:00-10:15 Moderators: junior investigators
Brief talks by junior investigators
Christina Lill: Risk prediction in Parkinson‘s disease

Coffee Break

Session 5
Brief talks by junior investigators
10:45-12:00 Moderators: junior investigators
Brief talks by junior investigators

Lunch 12:15-13:45

Session 6
Genetics & biomarkers of neurodegeneration in Parkinson‘s disease
14:10-14:25 Lars Bertram: The role of micro-RNAs in Alzheimer’s disease and Parkinson‘s disease
14:25-14:40 Christina Lill: Risk prediction in Parkinson‘s disease
14:40-14:55 Brit Mollenhauer: Emerging biomarkers in Parkinson‘s disease
14:55-15:10 Discussion (all)
Session 7
The heat is on: Inflammation in neurodegeneration
15:40-15:55 Christine von Arnim: Neuropsychiatric symptoms, stress and inflammation in dementia
15:55-16:10 Karin Danzer: The role of monocytes in Parkinson’s disease and amyotrophic lateral
sclerosis
16:10-16:25 Mikko Hiltunen: Microglial molecular regulatory networks in neurodegeneration
Session 8
Keynote lectures – moderator: Christine von Arnim
16:25-16:55 Bradley T. Hyman: How heterogeneous is Alzheimer’s disease clinically and biologically?
16:55-17:25 Rudy Tanzi: The innate immune hypothesis of Alzheimer’s Disease
17:25-17:55 Xandra Breakefield: Any parallels between neurodegeneration and brain tumors?
17:55-18:15 Discussion
[INTERNAL *18:15-19:00 Internal HEAT-NET members with mentors*]

Coffee: 8:30

Session 9
Biomarkers in Alzheimer’s disease and related disorders
9:00-9:15 Alberto Lleó: Cerebrospinal fluid biomarkers in early Alzheimer’s disease
9:15-9:30 Jens Wiltfang: Current and emerging molecular biomarkers for the blood-based early
diagnostics of Alzheimer’s disease
9:30-9:45 Inga Zerr: Biomarker research to understand molecular heterogeneity in
neurodegenerative diseases
9:45-10:00 Markus Otto: Fluid biomarkers in frontotemporal dementia and amyotrophic lateral
sclerosis – tbc

Coffee break 10:00-10:30

Session 10
Treating neurodegeneration: Present and Future
10:30-10:45 Andre Fischer: RNA and the epigenome as targets for stratified therapies in
neurodegenerative diseases
10:45-11:00 Martin Ingelsson: CRISPR/Cas9 as a novel gene therapy tool for neurodegenerative
diseases

Tee break 11:00-11:45

Session 11
Keynote lecture. Moderator: Martin Ingelsson
11:45-12:15 Lars Lannfelt: Targeting soluble aggregated Aβ with lecanemab (BAN2401) – from
mutation to potential therapy for Alzheimer’s disease
12:15-12:30 Discussion
[/fusion_table]
Closing session
Tiago Outeiro, Christine von Arnim, Martin Ingelsson, Alberto Lleó
13:00-13:45 Lars Lannfelt: Targeting soluble aggregated Aβ with lecanemab (BAN2401) – from
mutation to potential therapy for Alzheimer’s disease
14:00-16:00 Discussion
Funding options
Future plans

16:00 Joint social activity and transfer to the airport

Download the Program

Sponsoring